Exploring factors related to metastasis free survival in breast cancer patients using Bayesian cure models

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 22, 2014, Pages 9673-9678

  Jafari Koshki, Tohid ^a,b   Mansourian, Marjan ^b,c   Mokarian, Fariborz ^b  

^a SABZEVAR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bayesian; Breast cancer; Cure model; Metastasis; Survival

Indexed keywords

ADULT; AGED; BAYES THEOREM; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MIDDLE AGED; MORTALITY; PROGNOSIS; SECONDARY; STATISTICAL ANALYSIS; STATISTICAL MODEL; SURVIVAL RATE;

ADULT; AGED; BAYES THEOREM; BREAST NEOPLASMS; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; SURVIVAL RATE;

EID: 84921458399     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.22.9673     Document Type: Article

References (55)

1. Altundag K, Bondy ML, Mirza NQ, et al (2007). Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system Metastasis. Cancer, 110, 2640-7.
2. American Cancer Society (2011). Global cancer facts & figures 2nd edition; estimated number of new cancer cases by World Area, 2008.
3. Andre F, Slimane K, Bachelot T, et al (2004). Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Ontol, 22, 3302-8.
4. Babu GR, Samari G, Cohen SP, et al (2011). Breast cancer screening among females in Iran and recommendations for improved practice. Asian Pac J Cancer Prev, 12, 1647-55.
5. Balleine R, Earl M, Greenberg M, et al (1999). Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer, 79, 1564-71.
6. Basu S, Tiwari RC (2010). Breast cancer survival, competing risks and mixture cure model: a Bayesian analysis. J Royal Statist Soc, 173, 307-29.
7. Carter C, Allen C, Henson D (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63, 181-7.
8. Chen M-H, Ibrahim JG, Sinha D (1999). A new bayesian model for survival data with a surviving fraction. J Am Statistical Association, 94, 909-19.
9. Colleoni M, Rotmensz N, Peruzzotti G, et al (2005). Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol, 23.
10. Congdon PD 2010. Applied bayesian hierarchical methods, chapman & hall/CRC.
11. Eichler AF, Kuter I, Ryan P, et al (2008). Survival in patients with brain metastases from breast cancer. Cancer, 112, 2359-67.
12. Evans AJ, James JJ, Cornford EJ, et al (2004). Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol, 16, 345-9.
13. Foster TS, Miller JD, Boye ME, et al (2011). The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev, 37, 405-15.
14. Gao D, Du J, Cong L, et al (2009). Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages i-iii of operable patients. Jpn J Clin Oncol, 39, 97-104.
15. Garcia M, Platet N, Liaudet E, et al (1996). Biological and clinical significance of cathepsin d in breast cancer Metastasis. Stem Cells, 14, 642-50.
16. Ibrahim JG, Chen M-H, Sinha D (2001). Bayesian survival analysis, springer-verlag New York.
17. Inoue H, Kawada A, Takasu H, et al (1998). Cathepsin D expression in skin metastasis of breast cancer. J Cutaneous Pathology, 25, 365-9.
18. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90.
19. Johnston SRD (2010). Living with secondary breast cancer: coping with an uncertain future with unmet needs. European J Cancer Care, 19, 561-3.
20. Koizumi M, Yoshimoto M, Kasumi F, et al (2010). An open cohort study of bone metastasis incidence following surgery in breast cancer patients. BMC Cancer, 10, 381.
21. Koscielny S, Tubiana M, Le M, et al (1984). Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer, 49, 709-15.
22. Lamyian M, Hydarnia A, Ahmadi F, et al (2007). Barriers to and factors facilitating breast cancer screening among Iranian women: a qualitative study. East Med Health J, 13, 1160-9.
23. Largillier R, Ferrero J-M, Doyen J, et al (2008). Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol, 19, 2012-9.
24. Lunn D, Spiegelhalter D, Thomas A, et al (2009). The BUGS project: Evolution, critique, and future directions. Statistics in Medicine, 28, 3049-67.
25. Mayer M, Hunis A, Oratz R, et al (2010). Living with metastatic breast cancer: a global patient survey. Community Oncology, 7, 406-12.
26. Minisini AM, Moroso S, Gerratana L, et al (2013). Risk factors and survival outcomes in patients with brain metastases from breast cancer. clinical and experimental metastasis.
27. Montazeri A, Vahdaninia M, Harirchi I, et al (2008). Breast cancer in Iran: need for greater women awareness of warning signs and effective screening methods. Asia Pac Family Medicine, 7.
28. Morris PG, Murphy CG, Mallam D, et al (2012). Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast J, 1-6.
29. Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
30. Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91.
31. Nieder C, Marienhagenz K, Thammx R, et al (2008). Prediction of very short survival in patients with brain metastases from breast cancer. Clin Oncol, 20, 337-9.
32. Noroozi A, Jomand T, Tahmasebi R (2011). Determinants of breast self-examination performance among iranian women: an application of the health belief model. J Canc Educ, 26, 365-74.
33. Oltean D, Dicu T, Eniu D (2009). Brain metastases secondary to breast cancer: symptoms, prognosis and evolution. Tumori, 95, 697-701.
34. Othus M, Barlogie B, LeBlanc ML (2012a). Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res.
35. Othus M, Barlogie B, LeBlanc ML, et al (2012b). Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res, 18, 3731-6.
36. Palmieria D, Smithb QR, Lockmanb PR, et al (2006, 2007). Brain metastases of breast cancer. Breast Disease, 26, 139-47.
37. Rama R, Swaminathan R, Venkatesan P (2010). Cure models for estimating hospital-based breast cancer survival. Asian Pac J Cancer Prev, 11, 387-91.
38. Rochefort H, Capony F, Garcia M (1990). Cathepsin D: A protease involved in breast cancer metastasis. Cancer Metastasis Reviews, 9, 321-31.
39. Rochefort H, Liaudent-coopman E (1999). Cathepsin D in cancer metastasis: A protease and a ligand. APMIS, 107, 86-95.
40. Ruiterkamp J, Ernst MF, de Munck L, et al (2011). Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. Breast Cancer Res Treat, 128, 495-503.
41. Santen G, Danhof M, Della Pasqua O (2008). Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. J Psychiatric Res, 42, 1189-97.
42. Selzner M, Morse MA, Vredenburgh JJ, et al (2000). Liver metastases from breast cancer: long-term survival after curative resection. Surgery, 127, 383-9.
43. Senkus E, Cardoso F, Pagani O (2013). Time for more optimism in metastatic breast cancer? Cancer Treatment Reviews, 40, 220-8.
44. Sezgin C, Gokmen E, Esassolak M, et al (2007). Risk factors for central nervous system metastasis in patients with metastatic breast cancer. Medical Oncology, 24, 155-61.
45. Sposto R (2002). Cure model analysis in cancer: an application to data from the children's cancer group. Statist Med, 21, 293-312.
46. Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70.
47. Truong PT, Berthelet E, Lee J, et al (2005). The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer, 103, 2006-14.
48. Van Der Wal Bch, Butzelaar Rmjm, Van Der Meij S, et al (2002). Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol, 28, 481-9.
49. Veronesi U, Galimberti V, Zurrida S, et al (1993). Prognostic significance of number and level of axillary node metastases in breast cancer. The Breast, 2, 224-8.
50. Voogd AC, Cranenbroek S, de Boer R, et al (2005). Long-term prognosis of patients with axillary recurrence after axillary dissection for invasive breast cancer. European Journal of Surgical Oncol, 31, 485-9.
51. Wadasadawala T, Gupta S, Bagul V, et al (2007). Brain metastases from breast cancer: Management approach. Journal of Cancer Research and Therapeutics, 3, 157-65.
52. Weigelt B, Peterse JL, van 't Veer LJ (2005). Breast Cancer Metastasis: Markers and Models. Nature Reviews, Cancer, 5, 591-602.
53. Yamasaki S, Okino T, Kan N, et al (1992). Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy. J Cancer Res Clin Oncol, 118, 157-62.
54. Yin G, Ibrahim JG (2005). Cure rate models: a unified approach. Canadian J Statistics, 33, 559-70.
55. Yu XQ, De Angelis R, Andersson TML, et al (2013). Estimating the proportion cured of cancer: Some practical advice for users. Cancer Epidemiology, 37, 836-842.